An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.
Principal investigator: Katriina Jalkanen
HUS, Helsinki University Hospital, Comprehensive Cancer Center
